Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ACR | P10323 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23131831 | 0.89 | TP53 (0.45) | TP53CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL6371541 | 0.88 | MAPT (0.56) | TP53CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL346324 | 0.87 | HPGD (0.48) | TP53CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL13614144 | 0.86 | CYP1A2 (0.47) | TP53CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL2122462 | 0.85 | CYP1A2 (0.46) | TP53CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL892010 | 0.85 | CYP1A2 (0.46) | TP53CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL1166530 | 0.85 | MAPT (0.48) | TP53CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL15931414 | 0.85 | HPGD (0.58) | CYP1A2MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL6377856 | 0.85 | CYP1A2 (0.46) | TP53CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL15932116 | 0.84 | CYP4F2 (0.47) | TP53CYP1A2MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027089-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12502380-B2 | MrgprX2 antagonists for the treatment of inflammatory disorders | DERMIRA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2025133989-A1 | SMYD MODULATORS AND USES THEREOF | ALT-BIO PTE. LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| US-12319703-B2 | Macrocyclic fused pyrazoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250057816-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | REMYND N.V. (BE) | 2024-12-31 | — | — | US | disclosed |
| WO-2024245156-A1 | HETEROCYCLIC COMPOUND ACTING AS α5-GABAA RECEPTOR REGULATOR | 武汉人福创新药物研发中心有限公司 | 2024-12-05 | — | — | WO | disclosed |
| CN-119019425-A | Alpha 5-GABAAHeterocyclic compounds as receptor modulators | 武汉人福创新药物研发中心有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-114845709-B | MRGPRX2 antagonists for the treatment of inflammatory disorders | 德米拉公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2003093250-A2 | POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-0986562-B1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME (GB) | 2002-08-07 | — | — | EP | disclosed |
| US-6310203-B1 | Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands | MERCK SHARPE & DOHME LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6200975-B1 | FOR COGNITION ENHANCEMENT THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-0986562-A1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998050385-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
| EP-0399645-B1 | Tetrahydropyranyl derivatives, process for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1994-11-09 | — | — | EP | disclosed |
| EP-0316783-B1 | PROCESS FOR THE PREPARATION OF HETERO-AROMATIC KETONES AND ALDEHYDES | BASF Aktiengesellschaft (DE) | 1992-03-18 | — | — | EP | disclosed |
| EP-0399645-A2 | Tetrahydropyranyl derivatives, process for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1990-11-28 | — | — | EP | disclosed |
| EP-0316783-A1 | Process for the preparation of hetero-aromatic ketones and aldehydes | BASF Aktiengesellschaft (DE) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027089-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | TP53 4830/4885CYP1A2 486/4885MAPT 4728/4885 |
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | TP53 3428/4885CYP1A2 2523/4885MAPT 581/4885 |
| US-12319703-B2 | Macrocyclic fused pyrazoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | TP53 17/4885CYP1A2 1699/4885MAPT 2417/4885 |
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | PDE4A, PDE12, PDE2A | TP53 4506/4885CYP1A2 2964/4885MAPT 68/4885 |
| US-12502380-B2 | MrgprX2 antagonists for the treatment of inflammatory disorders | MRGPRX2, MRGPRX1, MRGPRX4 | TP53 4697/4885CYP1A2 1154/4885MAPT 3161/4885 |
| US-20250057816-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | TP53 4697/4885CYP1A2 1154/4885MAPT 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.